IOVA / Iovance Biotherapeutics, Inc. - SEC-Einreichungen, Jahresbericht, Proxy Statement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 7, 2026 IOVANCE BIOTHERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 7, 2026 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Empl

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates 1Q26 Total Revenue of ~$71M Delivers ~45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M 40% C

Exhibit 99.1 Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates 1Q26 Total Revenue of ~$71M Delivers ~45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M 40% Confirmed Objective Response Rate in Metastatic Serous Endometrial Cancer SAN CARLOS, Calif., May 7, 2026 - Iovance Biotherapeutics, Inc.

+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents +- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

ARS

2025 ANNUAL REPORT Advancing Our MissionDear Iovance Biotherapeutics Shareholders, 2025 was transformative for advancing our mission to be the global leader in TIL cell therapy innovation as we navigated our commercial launch, achieved meaningful clinical milestones and sharpened our focus on RSHUDWLRQDOH[FHOOHQFHDQGFRVWHưFLHQFLHVRQ WKHSDWKWRIXWXUHSURƮWDELOLW\:HDUHVWHDGIDVW in our c

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definitive Proxy Statemen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒Definit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 17, 2026 IOVANCE BIOTHERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 17, 2026 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. E

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates ~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annua

Exhibit 99.1 Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates ~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track Designation Granted for Lifileucel in Second-Line Advanced Non-Small Cell Lung Cancer SAN CARLOS, Calif.,

FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT

Exhibit 10.32 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed or constitutes personal information. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This FIRST AMENDMENT TO EXECUTIVE EMPLOYME

1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview February 2026 1

Exhibit 99.2 1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview February 2026 1 2 © 2026, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this presentation are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission file number: 001-3686

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 24, 2026 IOVANCE BIOTHER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 24, 2026 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 9, 2026 IOVANCE BIOTHERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 9, 2026 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S.

1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview January 2026 1

Exhibit 99.1 1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview January 2026 1 2 © 2026, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this presentation are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the

As filed with the Securities and Exchange Commission on November 12, 2025

As filed with the Securities and Exchange Commission on November 12, 2025 Registration No.

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 IOVANCE BIOTHERAPEUTICS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, par value $0.000041666 per share Other 1,000,000 $ 1.82 $ 1,820,000.00 0.0001381 $ 251.34

As filed with the Securities and Exchange Commission on November 12, 2025

As filed with the Securities and Exchange Commission on November 12, 2025 Registration No.

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 IOVANCE BIOTHERAPEUTICS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, par value $0.000041666 per share Other 13,089,141 $ 1.82 $ 23,822,236.62 0.0001381 $ 3,28

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 6, 2025 IOVANCE BIOTHERA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 6, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S.

+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents +- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Press Release of Iovance Biotherapeutics, Inc., dated November 6, 2025.

Exhibit 99.1 Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results Quarterly Revenue Growth of 13% to ~$68 Million Gross Margin Increased to 43% on Improved Execution and Operational Efficiency Best-in-Class Clinical Profile for Lifileucel in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) with Median Duration of Response Not R

EXECUTIVE EMPLOYMENT AGREEMENT

Exhibit 10.1 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed or constitutes personal information. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is enter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 29, 2025 IOVANCE BIOTHERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 29, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S.

1 © 2025, Iovance Biotherapeutics, Inc. © 2025, Iovance Biotherapeutics, Inc. Corporate Overview August 2025 1 2 © 2025, Iovance Biotherapeutics, Inc. Forward-Looking Statements Certain matters discussed in this presentation are “forward-looking stat

Exhibit 99.1 1 © 2025, Iovance Biotherapeutics, Inc. © 2025, Iovance Biotherapeutics, Inc. Corporate Overview August 2025 1 2 © 2025, Iovance Biotherapeutics, Inc. Forward-Looking Statements Certain matters discussed in this presentation are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Priva

Security Type

Calculation of Filing Fee Tables S-3 IOVANCE BIOTHERAPEUTICS, INC. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forwa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 22, 2025 IOVANCE BIOTHERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 22, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S.

AMENDED & RESTATED OPEN MARKET SALE AGREEMENTSM

Exhibit 1.1 AMENDED & RESTATED OPEN MARKET SALE AGREEMENTSM August 22, 2025 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Iovance Biotherapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares

Up to $350,000,000 Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-272718 PROSPECTUS SUPPLEMENT (To Prospectus dated June 16, 2023) Up to $350,000,000 Common Stock We entered into an Amended and Restated Open Market Sale Agreement SM, dated August 22, 2025, or the Sale Agreement, with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus supplement.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 18, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S.

Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy

Exhibit 99.1 Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., August 18, 2025 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 7, 2025 IOVANCE BIOTHERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 7, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. E

+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents +- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan, as amended.

Exhibit 10.1 IOVANCE BIOTHERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN AS AMENDED 1.Establishment, Purpose and Term of Plan. 1.1Establishment. The Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan (as amended from time to time, the “Plan”) is hereby established effective as of June 8, 2020, the date of its initial approval by the stockholders of the Company (the “Effective Date

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 $60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into

Exhibit 99.1 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 $60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reiterated SAN CARLOS, Calif., August 7, 2025 - Iovance Biotherapeutics, Inc. (NA

Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended.

Exhibit 10.2 IOVANCE BIOTHERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN AS AMENDED 1.Purpose. The Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (as amended from time to time, the “Plan”) is intended to help Iovance Biotherapeutics, Inc., a Delaware corporation (including any successor thereto, the “Company”), and its Affiliates attract and retain key personnel by providing them the opport

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

Exhibit 99.1 Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer SAN CARLOS, Calif., July 15, 2025 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Corleen Roche as Chief

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 15, 2025 IOVANCE BIOTHERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 15, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 30, 2025 IOVANCE BIOTHERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 30, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 10, 2025 IOVANCE BIOTHERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 10, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 10, 2025 IOVANCE BIOTHERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 10, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 8, 2025 IOVANCE BIOTHERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 8, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Empl

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025 1Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidan

Exhibit 99.1 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025 1Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for Amtagvi® Expected in the UK, EU, and Canada On Track to Report Updated Clinical Data for Regi

+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents +- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

ARS

24 ANNU AL REPORTDear Iovance Biotherapeutics Shareholders, 2024 was a monumental year for Iovance.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒Definit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definitive Proxy Statemen

Amendment #3 to the Cooperative Research and Development Agreement #02734, dated September 7, 2021, by and between the National Cancer Institute and Iovance Biotechnologies, Inc.**+

Exhibit 10.30 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. Amendment #3 Cooperative Research and Development Agreement # 02734 IC Principal Investigator: Steven A. Rosenberg, M.D., Ph.D.

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024 Significant Demand for Amtagvi® (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M in FY24, Achieving Upper End

Exhibit 99.1 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024 Significant Demand for Amtagvi® (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M in FY24, Achieving Upper End of FY24 Guidance Range of $160M-$165M Reaffirming FY25 Total Product Revenue Guidance of $450M-$475M FY25 Cash Burn Anticipated to be Un

Amendment #4 to the Cooperative Research and Development Agreement #02734, dated August 26, 2024, by and between the National Cancer Institute and Iovance Biotherapeutics, Inc.**+

Exhibit 10.31 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. Amendment #4 Cooperative Research and Development Agreement # 02734 IC Principal Investigator: Steven A. Rosenberg, M.D., Ph.D.

Executive Employment Agreement, effective as of January 25, 2025, by and between Daniel Gordon Kirby and Iovance Biotherapeutics, Inc.**+

Exhibit 10.43 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed or constitutes personal information. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is ente

Iovance Biotherapeutics, Inc. Dodd-Frank Clawback Policy.**

Exhibit 97.1 IOVANCE BIOTherapeutics, Inc. DODD-FRANK CLAWBACK POLICY Iovance Biotherapeutics, Inc. (the “Company”) has adopted this clawback policy (this “Policy”) as a supplement to any other clawback policies in effect now or in the future at the Company. To the extent this Policy applies to compensation payable to a person covered by this Policy, it shall be the only clawback policy applicable

Termination Agreement, effective as of November 15, 2024, by and between Iovance Biotherapeutics, Inc. and ARE – San Francisco No. 63, LLC.**

Exhibit 10.55 AGREEMENT FOR TERMINATION OF LEASE AND VOLUNTARY SURRENDER OF PREMISES This Agreement for Termination of Lease and Voluntary Surrender of Premises (this “Agreement”) is made and entered into as of November 15, 2024, by and between ARE-SAN FRANCISCO NO. 63, LLC, a Delaware limited liability company (“Landlord”), and IOVANCE BIOTHERAPEUTICS, INC., a Delaware corporation (“Tenant”), wit

Iovance Biotherapeutics, Inc. Insider Trading Policy.**

Exhibit 19.1 Iovance Biotherapeutics, Inc. Insider Trading Policy I.INTRODUCTION It is the policy of Iovance Biotechnologies, Inc. (the “Company”) that its employees and members of its Board of Directors comply fully with the insider trading securities laws and regulations of the United States, of the several states, and of foreign jurisdictions, wherever they are applicable. It is illegal for any

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 27, 2025 IOVANCE BIOTHER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 27, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S

Sublease, effective as of November 15, 2024, by and between Iovance Biotherapeutics, Inc. and Vaxcyte, Inc.**+

Exhibit 10.54 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed or constitutes personal information. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. SUBLEASE THIS SUBLEASE (this “Sublease”) is dated for reference purposes as of November 15,

Subsidiaries of the Company.**

Exhibit 21.1 Subsidiaries Of The Company Iovance Biotherapeutics GmbH, a company formed under the laws of Switzerland. Iovance Biotherapeutics B.V., a company formed under the laws of The Netherlands. Iovance Biotherapeutics Manufacturing LLC, a limited liability company formed under the laws of the Commonwealth of Pennsylvania. Iovance Biotherapeutics UK Ltd, a limited company formed under the la

Executive Employment Agreement, effective as of January 10, 2022, by and between Raj K. Puri, M.D., Ph.D. and Iovance Biotherapeutics, Inc.**+

Exhibit 10.42 Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed or constitutes personal information. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is ente

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission file number: 001-3686

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 10, 2025 IOVANCE BIOTHER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 10, 2025 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S

Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer

Exhibit 99.1 Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer SAN CARLOS, Calif., February 10, 2025 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Dan Kirby will join the Company’s e

Iovance Biotherapeutics, Inc. Amended and Restated 2021 Inducement Plan (filed herewith).

EXHIBIT 99.1 IOVANCE BIOTHERAPEUTICS, INC. AMENDED AND RESTATED 2021 INDUCEMENT PLAN IOVANCE BIOTHERAPEUTICS, INC. AMENDED AND RESTATED 2021 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purpose. The Iovance Biotherapeutics, Inc. Amended and Restated 2021 Inducement Equity Incentive Plan (as amended from time to time, the “Plan”) amends and restates, in its entirety, the Iovance Biotherapeutics, Inc. 2021 I

As filed with the Securities and Exchange Commission on December 13, 2024

As filed with the Securities and Exchange Commission on December 13, 2024 Registration No.

Filing Fee Table (filed herewith).

Calculation of Filing Fee Tables S-8 IOVANCE BIOTHERAPEUTICS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, par value $0.000041666 per share Other 2,000,000 $ 16,500,000.00 0.0001531 $ 2,526.15 Tot

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 15, 2024 IOVANCE BIOTHER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 15, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S

IOVA / Iovance Biotherapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Iovance Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.000041666 per share (Title of Class of Securities) 462260100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropri

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 7, 2024 IOVANCE BIOTHERA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 7, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S.

1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview November 2024 1

Exhibit 99.1 1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview November 2024 1 2 © 2024, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this presentation are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter re ferred to as the “Company,” “we,” “us,” or “our”) within the meaning of th

+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents +- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue Reaffirming Guidance of $160-$165M for FY

Exhibit 99.1 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue Reaffirming Guidance of $160-$165M for FY24 and $450-$475M for FY25 of Total Product Revenue Marketing Authorization Applications Validated and Accepted for Review by European Re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 7, 2024 IOVANCE BIOTHERA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 7, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S.

IOVA / Iovance Biotherapeutics, Inc. / STATE STREET CORP Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IOVANCE BIOTHERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 462260100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule

As filed with the Securities and Exchange Commission on August 8, 2024

As filed with the Securities and Exchange Commission on August 8, 2024 Registration No.

Filing Fee Table (filed herewith).

Calculation of Filing Fee Tables S-8 IOVANCE BIOTHERAPEUTICS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, par value $0.000041666 per share Other 500,000 $ 7.49 $ 3,745,000.00 0.0001476 $ 552.76 T

1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview August 2024 1

Exhibit 99.1 1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview August 2024 1 2 © 2024, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this press release are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter r eferred to as the “Company,” “we,” “us,” or “our”) within the meaning of the

As filed with the Securities and Exchange Commission on August 8, 2024

As filed with the Securities and Exchange Commission on August 8, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 8, 2024 IOVANCE BIOTHERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 8, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. E

Filing Fee Table (filed herewith).

Calculation of Filing Fee Tables S-8 IOVANCE BIOTHERAPEUTICS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, par value $0.000041666 per share Other 7,389,374 $ 7.49 $ 55,346,411.26 0.0001476 $ 8,169

Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended.

Exhibit 10.2 IOVANCE BIOTHERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN AS AMENDED 1.Purpose. The Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (as amended from time to time, the “Plan”) is intended to help Iovance Biotherapeutics, Inc., a Delaware corporation (including any successor thereto, the “Company”), and its Affiliates attract and retain key personnel by providing them the opport

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 8, 2024 IOVANCE BIOTHERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 8, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. E

+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents +- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan, as amended.

Exhibit 10.1 IOVANCE BIOTHERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN AS AMENDED 1.Establishment, Purpose and Term of Plan. 1.1.Establishment. The Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan (as amended from time to time, the “Plan”) is hereby established effective as of June 8, 2020, the date of its initial approval by the stockholders of the Company (the “Effective Dat

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024 Strong Momentum Continues for Amtagvi™ (Lifileucel) U.S. Launch with $31.1 Million in Total 2Q24 Revenue Total Product Revenue Guidance of

Exhibit 99.1 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024 Strong Momentum Continues for Amtagvi™ (Lifileucel) U.S. Launch with $31.1 Million in Total 2Q24 Revenue Total Product Revenue Guidance of $53-$55 Million for 3Q24, $160-$165 Million for FY24, and $450-$475 Million for FY25 SAN CARLOS, Calif., August 8, 2024 - Iovance Biother

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 28, 2024 IOVANCE BIOTHERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 28, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em

Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step in Global Expansion to Address

Exhibit 99.1 Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step in Global Expansion to Address >20,000 Patients Annually with Previously Treated Advanced Melanoma SAN CARLOS, Calif., June 28, 2024 - Iovance Biotherapeutics, Inc. (NA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 11, 2024 IOVANCE BIOTHERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 11, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 31, 2024 IOVANCE BIOTHERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 31, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Emp

1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview May 31, 2024 1

Exhibit 99.1 1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview May 31, 2024 1 2 © 2024, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this presentation are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter re ferred to as the “Company,” “we,” “U.S.,” or “our”) within the meaning of t

Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting Lifileucel TIL Cell Therapy in Combination with Pembrolizumab Demonstrates Deep, Durable Responses in Frontline Advanced Melanoma Patients in I

Exhibit 99.1 Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting Lifileucel TIL Cell Therapy in Combination with Pembrolizumab Demonstrates Deep, Durable Responses in Frontline Advanced Melanoma Patients in IOV-COM-202 Clinical Study ASCO Oral Presentation to Highlight 65% Objective Response Rate (ORR) and 30% Complete Response Rate Nearly All

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 23, 2024 IOVANCE BIOTHERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 23, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Emp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2)) ¨ Defini

Filing Fee Table (filed herewith).

Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Iovance Biotherapeutics, Inc.

As filed with the Securities and Exchange Commission on May 9, 2024

As filed with the Securities and Exchange Commission on May 9, 2024 Registration No.

+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents +- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Iovance Biotherapeutics, Inc. Amended and Restated 2021 Inducement Plan.

Exhibit 10.1 IOVANCE BIOTHERAPEUTICS, INC. AMENDED AND RESTATED 2021 INDUCEMENT PLAN IOVANCE BIOTHERAPEUTICS, INC. AMENDED AND RESTATED 2021 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purpose. The Iovance Biotherapeutics, Inc. Amended and Restated 2021 Inducement Equity Incentive Plan (as amended from time to time, the “Plan”) amends and restates, in its entirety, the Iovance Biotherapeutics, Inc. 2021 I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 9, 2024 IOVANCE BIOTHERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 9, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Empl

Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates Strong Momentum for Amtagvi™ (Lifileucel) U.S. Launch Following U.S. Food and Drug Administration (FDA) Approval 100+ Amtagvi Patients Enrolled Across More Tha

Exhibit 99.1 Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates Strong Momentum for Amtagvi™ (Lifileucel) U.S. Launch Following U.S. Food and Drug Administration (FDA) Approval 100+ Amtagvi Patients Enrolled Across More Than 40 Current Authorized Treatment Centers (ATCs), with ~50 Total ATCs On Track by End of May and 70+ Total ATCs by Year-End 2024 Amtagvi

Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended.

EXHIBIT 10.2 IOVANCE BIOTHERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN AS AMENDED 1.Purpose. The Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (as amended from time to time, the “Plan”) is intended to help Iovance Biotherapeutics, Inc., a Delaware corporation (including any successor thereto, the “Company”), and its Affiliates attract and retain key personnel by providing them the opport

ARS

ANNUAL REPORT 2023 A DECISIVE YEAR The U.S. Food and Drug Administration (FDA) approved Amtagvi™ (lifileucel) on February 16, 2024 as the first treatment option for advanced melanoma after anti-PD-1 and targeted therapy. This landmark approval also represents the first FDA-approved T cell therapy for a solid tumor cancer. Today, with our launch of Amtagvi, we are stepping up to start a new chapter of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒Definit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definitive Proxy Statemen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 3, 2024 IOVANCE BIOTHERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 3, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em

Delaware 19801 (the "Settlement Hearing"). This Notice describes the rights you may have under the Stipulation and what steps you may, but are not required to, take concerning the proposed Settlement. If the Court approves the Stipulation, the partie

Exhibit 99.1 LEO SHUMACHER, derivatively on behalf of IOVANCE BIOTHERAPEUTICS, INC., Plaintiff, V. IAIN DUKES, D.PHIL., MARIA FARDIS, PH.D., ATHENA COUNTOURIOTIS, M.D., RYAN D. MAYNARD, MERRILL A. MCPEAK, WAYNE P. ROTHBAUM, and MICHAEL WEISER, M.D., PH.D., Defendants, -and-IOV ANCE BIOTHERAPEUTICS, INC., Nominal Defendant. C.A. No. 2020-1049-PAF NOTICE OF PENDENCY OF SETTLEMENT OF ACTION TO: ALL C

Fourth Amended and Restated Bylaws of Iovance Biotherapeutics, Inc. (incorporated herein by reference to Exhibit 3.1 to Registrant’s Current Report on Form 8-K filed with the Commission on March 29, 2024).

Exhibit 3.1 FOURTH AMENDED AND RESTATED BYLAWS OF IOVANCE BIOTHERAPEUTICS, INC. (a Delaware corporation) As adopted by the Board of Directors on March 28, 2024 TABLE OF CONTENTS Page ARTICLE I CORPORATE OFFICES 1 1.1 REGISTERED OFFICE. 1 1.2 OTHER OFFICES. 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS. 1 2.2 ANNUAL MEETING. 1 2.3 SPECIAL MEETING. 1 2.4 ADVANCE NOTICE PROCEDURES FOR

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 26, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. E

IOVA / Iovance Biotherapeutics, Inc. / Quogue Capital LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Iovance Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.000041666 par value per share (Title of Class of Securities) 462260 10 0 (CUSIP Number) Wayne P. Rothbaum Quogue Capital LLC 101 Central Park West Suite 1F New York, New York 10019 (212) 554

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 4, 2024 IOVANCE BIOTHERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 4, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em

Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer

Exhibit 99.1 Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer SAN CARLOS, Calif., March 4, 2024 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer

AGREEMENT

EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: March 1, 2024 PERCEPTIVE ADVISORS LLC By:

IOVA / Iovance Biotherapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.  )* Iovance Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.000041666 per share (Title of Class of Securities) 462260 10 0 (CUSIP Number) February 20, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 28, 2024 IOVANCE BIOTHER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 28, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S

1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview February 28, 2024 1

Exhibit 99.1 1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview February 28, 2024 1 2 © 2024, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this press release are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter r eferred to as the “Company,” “we,” “us,” or “our”) within the meaning

Iovance Biotherapeutics, Inc. Dodd-Frank Clawback Policy.**

Exhibit 97.1 IOVANCE BIOTherapeutics, Inc. DODD-FRANK CLAWBACK POLICY Iovance Biotherapeutics, Inc. (the “Company”) has adopted this clawback policy (this “Policy”) as a supplement to any other clawback policies in effect now or in the future at the Company. To the extent this Policy applies to compensation payable to a person covered by this Policy, it shall be the only clawback policy applicable

Iovance Biotherapeutics, Inc. Insider Trading Policy.**

Exhibit 19.1 Iovance Biotherapeutics, Inc. Insider Trading Policy I.INTRODUCTION It is the policy of Iovance Biotechnologies, Inc. (the “Company”) that its employees and members of its Board of Directors comply fully with the insider trading securities laws and regulations of the United States, of the several states, and of foreign jurisdictions, wherever they are applicable. It is illegal for any

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission file number: 001-3686

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 28, 2024 IOVANCE BIOTHER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 28, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S

Subsidiaries of the Company.**

Exhibit 21.1 Subsidiaries Of The Company Iovance Biotherapeutics GmbH, a company formed under the laws of Switzerland. Iovance Biotherapeutics B.V., a company formed under the laws of The Netherlands. Iovance Biotherapeutics Manufacturing LLC, a limited liability company formed under the laws of the Commonwealth of Pennsylvania. Iovance Biotherapeutics UK Ltd, a limited company formed under the la

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates Amtagvi™ (lifileucel) U.S. Launch Fully Underway Following U.S. Food and Drug Administration (FDA) Approval as the First and Only One-Time, Indi

Exhibit 99.1 Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates Amtagvi™ (lifileucel) U.S. Launch Fully Underway Following U.S. Food and Drug Administration (FDA) Approval as the First and Only One-Time, Individualized T cell Therapy for a Solid Tumor Cancer Amtagvi Regulatory Submissions on Track in the European Union, United Kingdom, and Can

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 22, 2024 IOVANCE BIOTHER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 22, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S

23,014,000 Shares Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-272718 PROSPECTUS SUPPLEMENT (To Prospectus dated June 16, 2023) 23,014,000 Shares Common Stock We are offering 23,014,000 shares of our common stock. Our common stock trades on The Nasdaq Global Market under the symbol “IOVA.” On February 16, 2024, the last reported sales price of our common stock on The Nasdaq Global Marke

CALCULATION OF FILING FEE TABLE (Form Type) Iovance Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 CALCULATION OF FILING FEE TABLE 424(b)(5) (Form Type) Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock

Exhibit 99.1 Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock February 20, 2024 SAN CARLOS, Calif., February 20, 2024 - Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with

Underwriting Agreement, dated as of February 20, 2024 among Iovance Biotherapeutics, Inc., Jefferies LLC, Barclays Capital Inc. and Goldman Sachs & Co. LLC

Exhibit 1.1 23,014,000 Shares Iovance Biotherapeutics, Inc. UNDERWRITING AGREEMENT February 20, 2024 JEFFERIES LLC BARCLAYS CAPITAL INC. GOLDMAN SACHS & CO. LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 c/o Goldman Sachs & Co. LLC 200 West Street New York, New Yo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 16, 2024 IOVANCE BIOTHER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 16, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 20, 2024 IOVANCE BIOTHER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 20, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S

Iovance’s AMTAGVITM (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted ther

Exhibit 99.1 Iovance’s AMTAGVITM (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy AMTAGVI deploys patient-specific immune cells that recognize and fight cancer SAN CARLOS, Calif., February 16, 2024 - Iovance Biother

1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview February 16, 2024 1

Exhibit 99.2 1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview February 16, 2024 1 2 © 2024, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this press release are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter r eferred to as the “Company,” “we,” “us,” or “our”) within the meaning

IOVA / Iovance Biotherapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Iovance Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.000041666 per share (Title of Class of Securities) 462260 10 0 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropr

AGREEMENT

EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2024 PERCEPTIVE ADVISORS LLC

IOVA / Iovance Biotherapeutics, Inc. / Point72 Asset Management, L.P. - IOVANCE BIOTHERAPEUTICS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Iovance Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.000041666 per share (Title of Class of Securities) 462260100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

IOVA / Iovance Biotherapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Iovance Biotherapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 462260100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is

IOVA / Iovance Biotherapeutics, Inc. / MHR FUND MANAGEMENT LLC - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Iovance Biotherapeutics, Inc. (Name of Issuer) common stock, par value $0.000041666 (Title of Class of Securities) 462260 10 0 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

IOVA / Iovance Biotherapeutics, Inc. / BlackRock Inc. Passive Investment

us4622601007012624.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) IOVANCE BIOTHERAPEUTICS, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 462260100 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 25, 2024 IOVANCE BIOTHERA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 25, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S.

1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview January 25, 2024 1

Exhibit 99.1 1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview January 25, 2024 1 2 © 2024, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this press release are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter r eferred to as the “Company,” “we,” “us,” or “our”) within the meaning o

IOVA / Iovance Biotherapeutics, Inc. / STATE STREET CORP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMENDED FILING IOVANCE BIOTHERAPEUTICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 462260100 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDU

1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview January 2024 1

Exhibit 99.1 1 © 2024, Iovance Biotherapeutics, Inc. © 2024, Iovance Biotherapeutics, Inc. Corporate Overview January 2024 1 2 © 2024, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this press release are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter r eferred to as the “Company,” “we,” “us,” or “our”) within the meaning of th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 8, 2024 IOVANCE BIOTHERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 8, 2024 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S.

Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer

Exhibit 99.1 Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer December 27, 2023 SAN CARLOS, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today ann

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 27, 2023 IOVANCE BIOTHER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 27, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S

LETTER

United States securities and exchange commission logo November 21, 2023 Frederick G.

Annex A

DLA Piper LLP (US) 51 John F. Kennedy Parkway Suite 120 Short Hills, New Jersey 07078-2704 www.dlapiper.com Emilio Ragosa, Esq. [email protected] T   973.307.3004 F   973.215.2804 November 17, 2023 Attention: Ibolya Ignat, Senior Staff Accountant Li Xiao, Staff Accountant U.S. Securities & Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Wash

Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q filed with the Commission on November 7, 2023).#

Exhibit 10.2 IOVANCE BIOTHERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN AS AMENDED 1.Establishment, Purpose and Term of Plan. 1.1.Establishment. The Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan (as amended from time to time, the “Plan”) is hereby established effective as of June 8, 2020, the date of its initial approval by the stockholders of the Company (the “Effective Dat

+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents +- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Prescription Drug User Fee Act Ac

Exhibit 99.1 Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Prescription Drug User Fee Act Action (PDUFA) Date of February 24, 2023 Positive Regulatory Feedback Supports Lifileucel Regulatory Submissions in Europe and Canada in 20

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 7, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S.

Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed with the Commission on November 7, 2023).#

Exhibit 10.1 IOVANCE BIOTHERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN AS AMENDED 1.Purpose. The Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (as amended from time to time, the “Plan”) is intended to help Iovance Biotherapeutics, Inc., a Delaware corporation (including any successor thereto, the “Company”), and its Affiliates attract and retain key personnel by providing them the opport

IOVA / Iovance Biotherapeutics Inc / Quogue Capital LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Iovance Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.000041666 par value per share (Title of Class of Securities) 462260 10 0 (CUSIP Number) Wayne P. Rothbaum Quogue Capital LLC 101 Central Park West Suite 1F New York, New York 10019 (212) 554

LETTER

United States securities and exchange commission logo October 26, 2023 Frederick G.

U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma Priority Review Continues with Successful Facility Inspections Completed, no Major Review Issues FDA Ex

Exhibit 99.1 U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma Priority Review Continues with Successful Facility Inspections Completed, no Major Review Issues FDA Extends PDUFA Date to February 24, 2024 on Resource Constraints and Agrees to Work with Iovance to Expedite Remaining Review SAN CARLOS, Ca

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 15, 2023 IOVANCE BIOTHE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 15, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 16, 2023 IOVANCE BIOTHERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 16, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S.

Adam Schoenfeld, Memorial Sloan Kettering Cancer Center, New York, NY, USA 1. Multicenter Phase II Trial Of LN - 145 TIL Cell Therapy Plus Pembrolizumab in Patients With ICI - Naïve Metastatic NSCLC Adam Schoenfeld 1 ; Kai He 2 ; Jason Chesney 3 ; Ed

Exhibit 99.1 Adam Schoenfeld, Memorial Sloan Kettering Cancer Center, New York, NY, USA 1. Multicenter Phase II Trial Of LN - 145 TIL Cell Therapy Plus Pembrolizumab in Patients With ICI - Naïve Metastatic NSCLC Adam Schoenfeld 1 ; Kai He 2 ; Jason Chesney 3 ; Edward Garon 4 ; Jorge Nieva 5 ; Adrian Sacher 6 ; Sylvia Lee 7 ; Friedrich Graf Finckenstein 8 ; Rana Fiaz 8 ; Melissa Catlett 8 ; Guang C

1 © 2023, Iovance Biotherapeutics, Inc. © 2023, Iovance Biotherapeutics, Inc. Corporate Overview August 16, 2023 1

Exhibit 99.2 1 © 2023, Iovance Biotherapeutics, Inc. © 2023, Iovance Biotherapeutics, Inc. Corporate Overview August 16, 2023 1 2 © 2023, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this press release are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter r eferred to as the “Company,” “we,” “us,” or “our”) within the meaning of

Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Prescription Drug User Fee Act (PD

Exhibit 99.1 Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Prescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 Preparing for Potential Commercial Launch of Lifileucel as First Approved TIL Therapy in 2023 Post-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 8, 2023 IOVANCE BIOTHERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 8, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. E

+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents +- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 13, 2023 IOVANCE BIOTHERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 13, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em

Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering Offering Includes Exercise in Full of the Underwriters’ Option to Purchase an Additional 3 Million Shares of Common Stock

Exhibit 99.1 Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering Offering Includes Exercise in Full of the Underwriters’ Option to Purchase an Additional 3 Million Shares of Common Stock SAN CARLOS, Calif., July 13, 2023 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tum

20,000,000 Shares Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-272718 PROSPECTUS SUPPLEMENT (To Prospectus dated June 16, 2023) 20,000,000 Shares Common Stock We are offering 20,000,000 shares of our common stock. Our common stock trades on The Nasdaq Global Market under the symbol “IOVA.” On July 7, 2023, the last reported sales price of our common stock on The Nasdaq Global Market was

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 10, 2023 IOVANCE BIOTHERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 10, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em

CALCULATION OF FILING FEE TABLE (Form Type) Iovance Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 CALCULATION OF FILING FEE TABLE 424(b)(5) (Form Type) Iovance Biotherapeutics, Inc.

Underwriting Agreement, dated as of July 10, 2023 among Iovance Biotherapeutics, Inc., Goldman Sachs & Co. LLC and Jefferies LLC

Exhibit 1.1 20,000,000 Shares Iovance Biotherapeutics, Inc. UNDERWRITING AGREEMENT July 10, 2023 GOLDMAN SACHS & CO. LLC JEFFERIES LLC As Representatives of the several Underwriters c/o GOLDMAN SACHS & CO. LLC 200 West Street New York, New York 10282 c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. Iovance Biotherapeutics, Inc., a Delaware corporati

Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock

Exhibit 99.2 Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock SAN CARLOS, CA, July 10, 2023 - Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced

Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock

Exhibit 99.1 Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock SAN CARLOS, CA, July 10, 2023 - Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that it intends to off

Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer Positive FDA Feedback Supports IOV-LUN-202 Trial Design for Accelerated Approval of TIL Therapy in Post-Anti-PD-1 Advanced Non-Sm

Exhibit 99.1 Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer Positive FDA Feedback Supports IOV-LUN-202 Trial Design for Accelerated Approval of TIL Therapy in Post-Anti-PD-1 Advanced Non-Small Cell Lung Cancer (NSCLC) Preliminary Clinical Data in Post-Anti-PD-1 NSCLC Demonstrated a 26.1% Objective Response Rate (ORR) in Regi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 10, 2023 IOVANCE BIOTHERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 10, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em

Certificate of Incorporation, as amended, of Registrant (incorporated herein by reference to Exhibit 3.1 to Registrant’s Current Report on Form 8-K filed with the Commission on July 10, 2023).

Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF CONVERSION FROM A NON-DELAWARE CORPORATION TO A DELAWARE CORPORATION PURSUANT TO SECTION 265 OF THE DELAWARE GENERAL CORPORATION LAW 1. The jurisdiction where the Non-Delaware corporation first formed is Nevada. 2. The jurisdiction immediately prior to filing this Certificate is Nevada. 3. The date the Non-Delaware Corporation first formed is September

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 10, 2023 IOVANCE BIOTHERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 10, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em

SUBJECT TO COMPLETION, DATED JULY 10, 2023

TABLE OF CONTENTS The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed.

CALCULATION OF FILING FEE TABLE (Form Type) Iovance Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 CALCULATION OF FILING FEE TABLE 424(b)(5) (Form Type) Iovance Biotherapeutics, Inc.

Open Market Sale Agreement dated June 16, 2023, by and between Iovance Biotherapeutics, Inc. and Jefferies LLC.

Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM June 16, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Iovance Biotherapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s com

$450,000,000 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-272718 PROSPECTUS SUPPLEMENT (To Prospectus dated June 16, 2023) $450,000,000 Common Stock We entered into an Open Market Sales Agreement SM, dated June 16, 2023, or the Sales Agreement, with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus supplement. The Sales Agreement superseded and replaced the

Filing Fee Table (filed herewith).

Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Iovance Biotherapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 16, 2023 IOVANCE BIOTHERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 16, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Em

As filed with the Securities and Exchange Commission on June 16, 2023

As filed with the Securities and Exchange Commission on June 16, 2023 Registration No.

Form of Indenture (filed herewith).

Exhibit 4.1 IOVANCE BIOTHERAPEUTICS, INC. INDENTURE Dated as of [·] [·] Trustee TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01. Certain Terms Defined 1 Section 1.02. Other Definitions 6 Section 1.03. Rules of Construction 6 ARTICLE 2 SECURITY FORMS 7 Section 2.01. Forms Generally 7 Section 2.02. Guarantees by Guarantor; Form of Guarantee; Release of Guarantee 7 Section 2.03. Form of T

As filed with the Securities and Exchange Commission on June 12, 2023

As filed with the Securities and Exchange Commission on June 12, 2023 Registration No.

Filing Fee Table (filed herewith).

Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended.

Exhibit 99.1 IOVANCE BIOTHERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN AS AMENDED 1.             Purpose. The Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (as amended from time to time, the “Plan”) is intended to help Iovance Biotherapeutics, Inc., a Delaware corporation (including any successor thereto, the “Company”), and its Affiliates attract and retain key personnel by providing th

Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan, as amended.

Exhibit 99.1 IOVANCE BIOTHERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN AS AMENDED 1.             Establishment, Purpose and Term of Plan. 1.1.          Establishment. The Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan (as amended from time to time, the “Plan”) is hereby established effective as of June 8, 2020, the date of its initial approval by the stockholders of the Comp

As filed with the Securities and Exchange Commission on June 12, 2023

As filed with the Securities and Exchange Commission on June 12, 2023 Registration No.

Filing Fee Table (filed herewith).

Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Iovance Biotherapeutics, Inc.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 6, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Emp

1 Index to Combined Carve-out Financial Statements Report of Independent Auditors ...................................................................................................... 2 Combined Statement of Profit or Loss and Other Comprehensive In

Exhibit 99.1 Proleukin Business (Carve-out from Clinigen Limited) Combined carve-out financial statements For the years ended 30 June 2022, 2021, and as at 1 July, 2020 (Amounts expressed in United States Dollars) 1 Index to Combined Carve-out Financial Statements Report of Independent Auditors ...................................................................................................... 2

2 Index to Unaudited Interim Condensed Combined Carve-out Financial Statements Unaudited Interim Condensed Combined Statement of Profit or Loss and Other Comprehensive Income 3 Unaudited Interim Condensed Combined Statement of Financial Position ....

Exhibit 99.2 Proleukin Business (Carve-out from Clinigen Limited) Unaudited interim condensed combined carve-out financial statements Six months ended 31 December 2022 (Amounts expressed in United States Dollars) 2 Index to Unaudited Interim Condensed Combined Carve-out Financial Statements Unaudited Interim Condensed Combined Statement of Profit or Loss and Other Comprehensive Income 3 Unaudited

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 18, 2023 IO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 18, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS The following unaudited pro forma condensed combined financial statements present the combination of the historical financial statements of Iovance Biotherapeutics, Inc. (the “Company” or “Iovance”), and Clinigen SP Limited (a carve-out of the Proleukin Business from Clinigen (defined below)), which is referred to as Proleuki

Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma Priority Review Granted with Prescription Drug User Fee Act (PDUFA) Action Date o

Exhibit 99.1 Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma Priority Review Granted with Prescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 First Potential Approval of an Individualized, One-Time Cell Therapy for Patients with Advanced Melanoma SAN CARLOS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 26, 2023 IOVANCE BIOTHERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 26, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Emp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 18, 2023 IOVANCE BIOTHERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 18, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Emp

Filing Fee Table (filed herewith).

Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Iovance Biotherapeutics, Inc.

As filed with the Securities and Exchange Commission on May 10, 2023

As filed with the Securities and Exchange Commission on May 10, 2023 Registration No.

+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents +- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 9, 2023 IOVANCE BIOTHERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 9, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. Empl

Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates First Biologics License Application (BLA) Submission Completed in March 2023 Commercial Readiness Activities on track to Support Potential Commercial Launch of

Exhibit 99.1 Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates First Biologics License Application (BLA) Submission Completed in March 2023 Commercial Readiness Activities on track to Support Potential Commercial Launch of Lifileucel in 2023 SAN CARLOS, Calif., May 9, 2023 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company de

ARS

ANNUAL REPORT 2022DE AR SHAREHOLDERS: Throughout the year, we continued to prioritize our biologics license application (BLA) submission for lifileucel on behalf of patients with advanced melanoma who progress on or after anti-PD-1 therapy.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definitive Proxy Statemen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒Definit

LETTER

United States securities and exchange commission logo April 25, 2023 Frederick Vogt, Ph.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 18, 2023 IOVANCE BIOTHERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 18, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 24, 2023 IOVANCE BIOTHERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 24, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. E

Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma First TIL Therapy BLA Submission to U.S. Food and Drug Administration

Exhibit 99.1 Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma First TIL Therapy BLA Submission to U.S. Food and Drug Administration SAN CARLOS, Calif., March 24, 2023 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced it has compl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 10, 2023 IOVANCE BIOTHERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 10, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 28, 2023 IOVANCE BIOTHER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 28, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates First Biologics License Application (BLA) Submission on Track to Complete in 1Q23

Exhibit 99.1 Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates First Biologics License Application (BLA) Submission on Track to Complete in 1Q23 SAN CARLOS, Calif., February 28, 2023 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymph

Subsidiaries of the Company.**

Exhibit 21.1 Subsidiaries Of The Company Iovance Biotherapeutics GmbH, a company formed under the laws of Switzerland. Iovance Biotherapeutics B.V., a company formed under the laws of The Netherlands. Iovance Biotherapeutics Manufacturing LLC, a limited liability company formed under the laws of the Commonwealth of Pennsylvania. Iovance Biotherapeutics UK Ltd, a limited company formed under the la

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission file number: 001-3686

IOVA / Iovance Biotherapeutics Inc / Point72 Asset Management, L.P. - IOVANCE BIOTHERAPEUTICS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Iovance Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.000041666 per share (Title of Class of Securities) 462260100 (CUSIP Number) February 16, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru

IOVA / Iovance Biotherapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Iovance Biotherapeutics, Inc. (Name of Issuer) common stock, par value $0.000041666 (Title of Class of Securities) 462260 10 0 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t

AGREEMENT

EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2023 PERCEPTIVE ADVISORS LLC

IOVA / Iovance Biotherapeutics Inc / Avoro Capital Advisors LLC - IOVANCE BIOTHERAPEUTICS, INC. Passive Investment

SC 13G/A 1 p23-0587sc13ga.htm IOVANCE BIOTHERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* Iovance Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.000041666 per share (Title of Class of Securities) 462260100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing o

IOVA / Iovance Biotherapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Iovance Biotherapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 462260100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is

IOVA / Iovance Biotherapeutics Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* IOVANCE BIOTHERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 462260100 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi

IOVA / Iovance Biotherapeutics Inc / BlackRock Inc. Passive Investment

us4622601007020323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) IOVANCE BIOTHERAPEUTICS, INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 462260100 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu

IOVA / Iovance Biotherapeutics Inc / STATE STREET CORP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INITIAL FILING IOVANCE BIOTHERAPEUTICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 462260100 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 23, 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 23, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission

Option Agreement, dated January 23, 2023, by and among Iovance Biotherapeutics, Inc., Iovance Biotherapeutics UK Ltd, Clinigen Holdings Limited, Clinigen Healthcare Limited, and Clinigen, Inc. (incorporated herein by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K/A filed with the Commission on January 27, 2023).

Exhibit 10.1 EXECUTION VERSION CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) the registrant customarily and actually treats that information as private or confidential. Dated January 2023 Option Agreement relating to the operations of the Proleukin Bu

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 23, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S.

Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates Acquisition of Worldwide Rights to Proleukin® Provides Immediate and Ongoing Revenue and Secures IL-2 Supply for Clinical and Future Commercial TIL Therapy Positive FDA Feed

Exhibit 99.1 Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates Acquisition of Worldwide Rights to Proleukin® Provides Immediate and Ongoing Revenue and Secures IL-2 Supply for Clinical and Future Commercial TIL Therapy Positive FDA Feedback on Phase 3 Confirmatory Study in Frontline Advanced (Metastatic or Unresectable) Melanoma Positive Clinical Data in Anti-PD-1 Naïve

IOVA / Iovance Biotherapeutics Inc / Quogue Capital LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Iovance Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.000041666 par value per share (Title of Class of Securities) 462260 10 0 (CUSIP Number) Wayne P. Rothbaum Quogue Capital LLC 101 Central Park West Suite 1F New York, New York 10019 (212) 554

1 © 2023, Iovance Biotherapeutics, Inc. © 2023, Iovance Biotherapeutics, Inc. Corporate OverviewJanuary 20231 3 © 2023, Iovance Biotherapeutics, Inc. Global Leadership in Innovating, Developing and Delivering TIL Therapy for Patients with Cancer Acti

Exhibit 99.1 1 © 2023, Iovance Biotherapeutics, Inc. © 2023, Iovance Biotherapeutics, Inc. Corporate OverviewJanuary 20231 2 © 2023, Iovance Biotherapeutics, Inc. Forward-Looking StatementsCertain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Privat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 10, 2023 IOVANCE BIOTHERA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 10, 2023 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S.

IOVA / Iovance Biotherapeutics Inc / MHR FUND MANAGEMENT LLC - SC 13G Passive Investment

SC 13G 1 d277539dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Iovance Biotherapeutics, Inc. (Name of Issuer) common stock, par value $0.000041666 (Title of Class of Securities) 462260 10 0 (CUSIP Number) December 22, 2022 (Date of Event Which Requires Filing of this Statement) Check

JOINT FILING AGREEMENT

EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that this Initial Statement on Schedule 13G with respect to the shares of Common Stock of Iovance Biotherapeutics, Inc., dated as of December 30, 2022, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in

Open Market Sale Agreement dated November 18, 2022, by and between Iovance Biotherapeutics, Inc. and Jefferies LLC.

Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM November 18, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Iovance Biotherapeutics, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s

$500,000,000 Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-238724 PROSPECTUS SUPPLEMENT (To Prospectus dated May 27, 2020) $500,000,000 Common Stock We have entered into an Open Market Sales Agreement SM, or the Sales Agreement, dated November 18, 2022, with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus supplement. This Sales Agreemen

Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma BLA Submission Ongoing with U.S. Food and Drug Administration

Exhibit 99.1 PRIVILEGED AND CONFIDENTIAL Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma BLA Submission Ongoing with U.S. Food and Drug Administration SAN CARLOS, Calif., November 18, 2022 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) today announced that its ongoing rolling Biologics License Application (BLA) submission to t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 18, 2022 IOVANCE BIOTHER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 18, 2022 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S

Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting 31% Objective Response Rate (ORR) and Median Duration of Response (mDOR) Not Reached at 36.5 Mont

Exhibit 99.2 Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting 31% Objective Response Rate (ORR) and Median Duration of Response (mDOR) Not Reached at 36.5 Months Median Study Follow Up in C-144-01 Trial (Cohorts 2 and 4) 42% of Responses Lasted for 24+ Months SITC Update and KOL Panel Webcast Th

1 © 2022, Iovance Biotherapeutics, Inc. © 2022, Iovance Biotherapeutics, Inc. Iovance Investor Event & KOL Roundtable Society for Immunotherapy of Cancer (SITC) Annual Meeting November 10, 2022 1 #SITC22

Exhibit 99.3 1 © 2022, Iovance Biotherapeutics, Inc. © 2022, Iovance Biotherapeutics, Inc. Iovance Investor Event & KOL Roundtable Society for Immunotherapy of Cancer (SITC) Annual Meeting November 10, 2022 1 #SITC22 2 © 2022, Iovance Biotherapeutics, Inc. Agenda Introduction – Friedrich Graf Finckenstein , M.D., Chief Medical Officer, Iovance Presentation Summary C - 144 - 01 Study in Advanced Me

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 18, 2022 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S

CALCULATION OF FILING FEE TABLE (Form Type) Iovance Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 CALCULATION OF FILING FEE TABLE 424(b)(5) (Form Type) Iovance Biotherapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 3, 2022 IOVANCE BIOTHERA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 3, 2022 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S.

Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates First Biologics License Application (BLA) Submission Initiated and on Track to Complete in 4Q22

Exhibit 99.1 Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates First Biologics License Application (BLA) Submission Initiated and on Track to Complete in 4Q22 SAN CARLOS, Calif., November 3, 2022 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor inf

+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents +- ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 12, 2022 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.

Notice of Pendency of Settlement of Action, dated August 31, 2022.

Exhibit 99.1

1 © 2022, Iovance Biotherapeutics, Inc. © 2022, Iovance Biotherapeutics, Inc. Corporate Overview August 25, 2022 1

Exhibit 99.2 1 ? 2022, Iovance Biotherapeutics, Inc. ? 2022, Iovance Biotherapeutics, Inc. Corporate Overview August 25, 2022 1 2 ? 2022, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this presentation are ?forward - looking statements? of Iovance Biotherapeutics, Inc. (hereinafter re ferred to as the ?Company,? ?we,? ?us,? or ?our?) within the meaning of

Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma First TIL Therapy BLA Submission Initiated with U.S. Food and Drug Administration Complete BLA Submission on Track for Fourth Quarter

Exhibit 99.1 Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma First TIL Therapy BLA Submission Initiated with U.S. Food and Drug Administration Complete BLA Submission on Track for Fourth Quarter 2022 SAN CARLOS, Calif., August 25, 2022 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing n

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 25, 2022 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S.

Form of Deferred Stock Unit Notice and Deferred Stock Unit Agreement under the Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q filed with the Commission on August 4, 2022).#

Exhibit 10.2 ? IOVANCE BIOTHERAPEUTICS, INC. DEFERRED RESTRICTED STOCK UNIT NOTICE UNDER THE IOVANCE BIOTHERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN, AS AMENDED Name of Grantee: This Notice evidences the award of Deferred Restricted Stock Units (each, a "DRSU," and collectively, the "DRSUs") of Iovance Biotherapeutics, Inc., a Delaware corporation (the "Company"), that have been granted to you pu

+- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents +- ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended.

Exhibit 10.1 ? IOVANCE BIOTHERAPEUTICS, INC. ? 2018 EQUITY INCENTIVE PLAN AS AMENDED ? 1. Purpose. The Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (as amended from time to time, the ?Plan?) is intended to help Iovance Biotherapeutics, Inc., a Delaware corporation (including any successor thereto, the ?Company?), and its Affiliates attract and retain key personnel by providing them the

Filing Fee Table (filed herewith).

Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Iovance Biotherapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 4, 2022 IOVANCE BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State of Incorporation) 001-36860 75-3254381 Commission File Number (I.R.S. E

As filed with the Securities and Exchange Commission on August 4, 2022

As filed with the Securities and Exchange Commission on August 4, 2022 Registration No.

Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates First Biologics License Application (BLA) Submission on Track in August 2022

Exhibit 99.1 Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates First Biologics License Application (BLA) Submission on Track in August 2022 SAN CARLOS, Calif., August 4, 2022 - Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte,